focus -WSS

focus

author：hotspot 2025-09-28 02:32:43 - browse：259

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Merck drug for rare lung condition set for approval in U.S.

WSS

Study says nonprofit hospitals fall short in charity care spending

Eliminate the waiting period for sterilization covered by Medicaid

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Abortion pill case raises question: who can sue the FDA?

Former reverend arrested for allegedly killing 8

CDC Director Mandy Cohen on transparency, trust, and health

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

Abortion pill case raises question: who can sue the FDA?

Cancer drug shortages should be causing more outrage

Decaf coffee targeted by food safety group under obscure FDA rule

Duchenne breakthrough therapy leaves behind pioneering families

Why patients can’t get everything they want on drug pricing

In age of alternative facts, a scholarly course on calling out crap

Biden warns of ‘dark winter’ during final presidental debate

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: mifepristone case, GLP

hotspot

Scientists boost immune system in aging mice by making it youthful

Washington mulls new rules to avert another Change Healthcare

Dems pitch expanding Medicare power to negotiate drug prices

Will the FTC rein in IQVIA's health data empire?

Search called off for baby washed away in Pennsylvania flash flood

Patient advocates debate FDA's accelerated approval process

knowledge

hotspot

hotspot

entertainment